CA19-9 promotes liver metastasis of pancreatic cancer through E-selectin mediated extravasation
Authors:
- Satoshi OgawaSOSatoshi Ogawa
- Hyemin SongHSHyemin Song
- Jasper HsuJHJasper Hsu
- Vasiliki PantazopoulouVPVasiliki Pantazopoulou
- Victoria Osorio-VasquezVOVictoria Osorio-Vasquez
- Casie S. KubotaCKCasie S. Kubota
- Chelsea R. BottomleyCBChelsea R. Bottomley
- Kathryn LandeKLKathryn Lande
- Jonathan ZhuJZJonathan Zhu
- Kristina L. PeckKPKristina L. Peck
Preprint
Abstract
Pancreatic ductal adenocarcinoma (PDAC) frequently metastasizes to the liver, which drives patient mortality. CA19-9 is elevated in most PDAC tumors and is widely used as a clinical biomarker. Elevated serum levels are associated with poor outcomes. However, whether CA19-9 functionally contributes to metastatic progression has not been fully defined, in part because mice lack endogenous CA19-9 expression. Here, using syngeneic murine PDAC cells engineered to express CA19-9, we investigated its functional role in liver metastasis. In splenic injection models, CA19-9 expression markedly increased liver metastatic burden by promoting both metastatic seeding and subsequent metastatic outgrowth. In vitro , CA19-9 enhanced tumor cell adhesion to endothelial cells through interaction with E-selectin. Metastatic seeding of CA19-9-expressing cells was reduced by genetic deletion of E-selectin or antibody neutralization of either CA19-9 or E-selectin in vivo . Therapeutic targeting of CA19-9 with a neutralizing antibody markedly reduced liver metastatic burden after metastatic seeding. CA19-9 expression increased AKT signaling in PDAC cells and liver metastases, and CA19-9 levels correlated with AKT activation in human PDAC tissues. These findings show that CA19-9 promotes PDAC liver metastasis through E-selectin-dependent metastatic seeding and AKT-associated metastatic outgrowth, highlighting CA19-9 as a functional mediator of PDAC metastasis and a potential therapeutic target.Keywords
Funding Information
- Pioneer Fund Postdoctoral Scholar Award
- Salk Institute Cancer Training Grant (T32CA009370)
- Mission Cure Capital LLC
- Conrad Prebys Foundation
- Paul M. Angell Family Foundation
- Pancreatic Cancer Action Network (19-20-ENGL)
- Curebound (20DG11)
- Helen McLoraine Developmental Chair
- National Cancer Institute (P01 CA265762)
- Emerald Foundation
- NIH-NCI CCSG (P30 CA014195)
- NIH-NIA San Diego Nathan Shock Center (P30 AG068635)
- Leona M. and Harry B. Helmsley Charitable Trust
- National Cancer Institute Cancer Center Support Grant (P30 CA231100)
This publication has 40 references indexed in Scilit:
- Pancreatic CancerJAMA, 2021
- Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoterBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2021
- Glycosylation in the Era of Cancer-Targeted Therapy: Where Are We Heading?Cancer Cell, 2019
- Cancer-associated mucins: role in immune modulation and metastasisCancer and Metastasis Reviews, 2019
- Tumor Metastasis: Molecular Insights and Evolving ParadigmsCell, 2011
- Glycan reductive isotope labeling for quantitative glycomicsAnalytical Biochemistry, 2009
- Involvement of adhesion molecules in metastasis of SW1990, human pancreatic cancer cellsJournal of Surgical Oncology, 1998
- Liver endothelial E-selectin mediates carcinoma cell adhesion and promotes liver metastasisInternational Journal of Cancer, 1997
- Characterization of E-selectin-deficient mice: Demonstration of overlapping function of the endothelial selectinsImmunity, 1994
- Importance of E‐selectin (ELAM‐1) and sialyl lewisa in the adhesion of pancreatic carcinoma cells to acttvated endotheliumInternational Journal of Cancer, 1993